ESMO China–International Dialogue | Meeting at the Summit: How China’s Innovative ADCs sac-TMT and A166 Are Reshaping the Breast Cancer Treatment Landscape 

ESMO China–International Dialogue | Meeting at the Summit: How China’s Innovative ADCs sac-TMT and A166 Are Reshaping the Breast Cancer Treatment Landscape 

2025.12.08
 At the 2025 European Society for Medical Oncology (ESMO) Annual Congress, Chinese innovative drugs and clinical research drew global attention. During the meeting, Xichun Hu, Professor at Fudan University Shanghai Cancer Center, presented a Late-Breaking Abstract (LBA) detailing the pivotal phase III study in which China’s first original HER2-targeted antibody–drug conjugate (ADC), A166 (budotituzumab vedotin), successfully challenged T-DM1 in the second-line setting for HER2-positive breast cancer. Based on this study, A166 received approval from the National Medical Products Administration (NMPA) on October 17, 2025, bringing a new standard-of-care option to clinical practice. 
ILCA Roundtable | MDT: Optimizing HCC Treatment Strategies – Insights from the TALENT Series Studies

ILCA Roundtable | MDT: Optimizing HCC Treatment Strategies – Insights from the TALENT Series Studies

2025.12.01
In recent years, advances in systemic therapy have offered hope for advanced liver cancer patients, but traditional single treatments remain limited, highlighting the need for new approaches. Combining systemic therapy with local treatments has become a key trend, with multidisciplinary team (MDT) collaboration now a global standard. Experts from surgery, interventional radiology, oncology, and more work together to design optimal, personalized treatment plans—from diagnosis and strategy development to timing of therapy and long-term follow-up.